Pharmacogenetics of Drug Hypersensitivity

10.1097/01.all.0000173785.81024.33

10.1016/S0140-6736(00)02799-9

10.1073/pnas.0409500102

10.1097/FPC.0b013e328330a3b8

10.1038/428486a

10.1111/j.1528-1167.2007.01022.x

10.1111/j.1528-1167.2008.01719.x

10.1097/FPC.0b013e3282f3ef9c

10.1001/archderm.1987.01660330082014

10.1016/S0140-6736(02)07873-X

10.1016/S0140-6736(02)08158-8

10.1097/00002030-200501030-00014

10.1097/01.aids.0000238408.82947.09

10.1097/QAD.0b013e32801199d9

10.1097/FPC.0b013e32831d0faf

10.1097/01.fpc.0000199500.46842.4a

10.2217/14622416.7.6.813

10.1212/WNL.56.7.890

10.1016/S1081-1206(10)62997-3

10.1097/QAD.0b013e3282f37812

10.1136/gut.47.5.717

10.1016/S0016-5085(99)70404-X

Donaldson PT , BhatnagarP, GrahamJ et al. Susceptibility to drug induced liver injury determined by HLA Class II genotype. Presented at: 59th Annual Meeting of the American Association for the Study of Liver Diseases. CA, USA. Hepatology 48(Suppl.) , 345 (2008).

10.1055/s-0029-1240009

10.1038/ng.379

10.1038/sj.tpj.6500458

10.1016/S0190-9622(97)80347-7

10.1016/S0190-9622(94)70007-9

10.1067/mjd.2001.117854

10.1001/archpsyc.1990.01810220061007

10.1016/0167-5699(90)90109-M

10.1016/S0140-6736(80)91554-8

10.1007/s00403-008-0895-5

10.1111/j.1365-2222.2004.02197.x

10.2217/14622416.9.1.85

Rodriguez-Perez M , Gonzalez-DominguezJ, MataranL et al. Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate. J. Rheumatol. 21 , 41–43 (1994).

10.1111/j.1399-0039.1985.tb00932.x

10.1016/S0091-6749(99)70243-5

10.1136/bmj.286.6362.338

Pachoula-Papasteriades C , BokiK, Varla-LeftherioticM et al.: HLA-A-B- and -DR antigens in relation to gold and d-penicillamine toxicity in Greek patients with RA.Dis. Markers4 , 35–41 (1986).

10.1016/j.iac.2009.04.007

10.2332/allergolint.55.1

10.1001/archderm.145.1.67

10.1111/j.1365-2133.2007.08167.x

10.1111/j.1346-8138.2005.tb00885.x

10.1111/j.1365-2133.2006.07332.x

10.1038/clpt.1992.8

10.1016/j.autrev.2009.02.029

10.1126/science.1071059

10.1016/S0300-483X(00)00397-8

10.2332/allergolint.55.17

10.1001/archderm.1997.03890460044005

10.1111/j.1365

10.1001/archderm.1993.01680220104023

10.2165/00002018-199308010-00008

10.1086/342571

10.1111/j.1365-2230.2009.03508.x

10.1038/nm.1884

10.1111/j.1365-2133.2009.09357.x

10.1016/S0002-9440(10)64284-8

10.1046/j.1523-1747.2002.01622.x

Phillips E , MallalS: HLA and drug-induced toxicity:Curr. Opin. Mol. Ther.11 , 231–242 (2009).

10.1016/j.jclinepi.2009.09.006

10.1016/S0149-2918(01)80132-6

Shapiro M , WardKM, SternJJ: A near fatal hypersensitivity reaction to abacavir: case report and literature review.AIDS Read.11 , 222–226 (2001).

10.1016/S0149-2918(02)85132-3

10.1345/aph.1A022

10.1517/phgs.5.2.203.27481

Hernandez J , CutrellA, BennyT et al.: Diagnosis of abacavir hypersensitivity reactions among patients not receiving abacavir in two blinded studies.Antivir. Ther.8 , L88 (2003).

10.1086/424009

10.1001/jama.296.7.769

Dart Trial Team: Twenty-four week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA) Trop. Med. Int. Health13 , 6–16 (2008).

10.1097/00002030-200211080-00017

10.1097/01.aids.0000171414.99409.fb

10.1097/QAD.0b013e3282f7cb60

10.1056/NEJMoa0706135

10.1086/529382

10.1086/504874

10.1097/QAI.0b013e318046ea31

Reeves I , ChurchillD, FisherM. Screening for HLA-B*5701 reduces the frequencies of abacavir hypersensitivity reactions. Antiviral Ther.11(Suppl. 3) , 14 (2006).

Trottier B ThomasR NguyenVK MachoufN: How effectively HLA screening can reduce the early discontinuation of abacavir in real life. Presented at: International AIDS Society Meeting. Sydney Australia July 22–25 (2007) (Abstract MOPEB002).

10.1111/j.1399-0039.2009.01383.x

10.1097/QAD.0b013e328273bc07

10.1097/QAD.0b013e32830719aa

10.1016/j.immuni.2008.04.020

10.1177/135965350801300202

10.1097/QAD.0b013e3280119579

Phillips E , NolanD, ThorbornD et al.: Genetic factors predicting abacavir hypersensitivity and tolerance in HLA-B*5701 positive individuals.Eur. J. Dermatol.18 , 247 (2008).

10.1097/ACI.0b013e32825ea68a

Shenton JM PopovicM UetrechtJP: Nevirapine hypersensitivity. In: Drug Hypersensitivity . Pichler WJ (Ed.) Karger AG Basel Switzerland 115–128 (2007).

10.1186/1742-6405-6-22

10.1097/01.aids.0000171419.29905.93

10.2165/00002018-199921060-00005

10.1007/s11096-004-1736-z

10.1097/01.fpc.0000189800.88596.7a

10.1016/0006-2952(95)02008-X

10.2217/14622416.9.11.1617

10.1111/j.1528-1167.2009.02269.x

10.1038/sj.tpj.6500356

10.1086/605292

10.1001/jama.300.5.555

10.1007/BF03256308

10.1177/135965350701200708

10.1111/j.1399-0039.2005.00401.x

10.1111/j.1399-0039.2007.00840.x

10.1097/01.fpc.0000197468.16126.cd

10.1086/591184

10.1038/gene.2009.58

Phillips EJ MallalSA: Chapter 20: HLA and drug reactions. In: The HLA Complex in Biology and Medicine a Resource Book . Narinder K Mehra (Ed.). Jaypee Brothers New Delhi India (2010).

Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 1 December 2009 1–161 www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (Accessed 21December2009)